Login to Your Account

Financings Roundup

Late-Stage Antibiotic Firm Trius Prices $45M Offering

By Jennifer Boggs
Managing Editor

Friday, January 27, 2012
A little more than a month after reporting positive data from the first of two pivotal trials testing antibiotic tedizolid phosphate in Gram-positive skin infections, Trius Therapeutics Inc. is shoring up its cash balance with a $45.2 million public offering.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription